These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9527274)

  • 1. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients.
    Ng EH; Ji CY; Tan PH; Lin V; Soo KC; Lee KO
    Ann Surg Oncol; 1998 Mar; 5(2):194-201. PubMed ID: 9527274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.
    Favoni RE; de Cupis A; Perrotta A; Sforzini S; Amoroso D; Pensa F; Miglietta L
    J Cancer Res Clin Oncol; 1995; 121(11):674-82. PubMed ID: 7593132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk.
    Ho GH; Luo XW; Ji CY; Foo SC; Ng EH
    Ann Acad Med Singap; 1998 Mar; 27(2):294-9. PubMed ID: 9663330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer.
    Pazaitou-Panayiotou K; Kelesidis T; Kelesidis I; Kaprara A; Blakeman J; Vainas I; Mpousoulegas A; Williams CJ; Mantzoros C
    Eur J Endocrinol; 2007 Feb; 156(2):187-94. PubMed ID: 17287408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status.
    Barnes BB; Chang-Claude J; Flesch-Janys D; Kinscherf R; Schmidt M; Slanger T; Bonaterra G; Steindorf K
    Cancer Causes Control; 2009 Dec; 20(10):1985-96. PubMed ID: 19597750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF status is altered by tamoxifen in patients with breast cancer.
    Campbell MJ; Woodside JV; Secker-Walker J; Titcomb A; Leathem AJ
    Mol Pathol; 2001 Oct; 54(5):307-10. PubMed ID: 11577172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.
    Kaaks R; Toniolo P; Akhmedkhanov A; Lukanova A; Biessy C; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E
    J Natl Cancer Inst; 2000 Oct; 92(19):1592-600. PubMed ID: 11018095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study.
    Wu MH; Chou YC; Chou WY; Hsu GC; Chu CH; Yu CP; Yu JC; Sun CA
    Int J Cancer; 2010 Jan; 126(2):508-14. PubMed ID: 19585556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study.
    Ho GH; Ji CY; Phang BH; Lee KO; Soo KC; Ng EH
    Ann Surg Oncol; 1998 Jun; 5(4):361-7. PubMed ID: 9641459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden.
    Kaaks R; Lundin E; Rinaldi S; Manjer J; Biessy C; Söderberg S; Lenner P; Janzon L; Riboli E; Berglund G; Hallmans G
    Cancer Causes Control; 2002 May; 13(4):307-16. PubMed ID: 12074500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.
    Yamaguchi T; Kanatani M; Yamauchi M; Kaji H; Sugishita T; Baylink DJ; Mohan S; Chihara K; Sugimoto T
    Calcif Tissue Int; 2006 Jan; 78(1):18-24. PubMed ID: 16397738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen.
    Lahti EI; Knip M; Laatikainen TJ
    Cancer; 1994 Jul; 74(2):618-24. PubMed ID: 7518340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
    J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer.
    Rollison DE; Newschaffer CJ; Tao Y; Pollak M; Helzlsouer KJ
    Int J Cancer; 2006 Mar; 118(5):1279-84. PubMed ID: 16161053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.